Press coverage about Pharmerica Corporation (NYSE:PMC) has trended somewhat positive recently, Accern reports. The research firm rates the sentiment of news coverage by reviewing more than twenty million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Pharmerica Corporation earned a news sentiment score of 0.14 on Accern’s scale. Accern also assigned news stories about the company an impact score of 66 out of 100, meaning that recent news coverage is likely to have an impact on the company’s share price in the near future.

Insider Buying and Selling by Quarter for Pharmerica Corporation (NYSE:PMC)

Shares of Pharmerica Corporation (NYSE PMC) traded down 0.79% during midday trading on Wednesday, hitting $25.00. 116,176 shares of the stock were exchanged. The stock has a market cap of $777.35 million, a P/E ratio of 37.31 and a beta of 0.97. The stock’s 50-day moving average price is $25.09 and its 200 day moving average price is $24.65. Pharmerica Corporation has a one year low of $19.20 and a one year high of $28.72.

Pharmerica Corporation (NYSE:PMC) last released its earnings results on Wednesday, May 10th. The company reported $0.42 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.40 by $0.02. The firm had revenue of $566.80 million for the quarter, compared to analysts’ expectations of $536.85 million. Pharmerica Corporation had a return on equity of 11.03% and a net margin of 0.98%. The business’s quarterly revenue was up 8.1% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.45 EPS. On average, analysts anticipate that Pharmerica Corporation will post $1.92 earnings per share for the current year.

Several research analysts have issued reports on PMC shares. Zacks Investment Research downgraded shares of Pharmerica Corporation from a “hold” rating to a “sell” rating in a research report on Tuesday, February 28th. ValuEngine cut shares of Pharmerica Corporation from a “buy” rating to a “hold” rating in a research note on Friday, June 2nd.

COPYRIGHT VIOLATION WARNING: This article was posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this article on another domain, it was stolen and republished in violation of U.S. & international copyright and trademark laws. The original version of this article can be accessed at

Pharmerica Corporation Company Profile

Receive News & Stock Ratings for Pharmerica Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pharmerica Corporation and related stocks with our FREE daily email newsletter.